Calming the cytokine storm of COVID-19 through inhibition of JAK2/STAT3 signaling

被引：31
作者：
Gajjela, Bharath Kumar [1 ]
Zhou, Ming-Ming [1 ]
机构：
[1] Icahn Sch Med Mt Sinai, Dept Pharmacol Sci, New York, NY 10029 USA
来源：
DRUG DISCOVERY TODAY | 2022年 / 27卷 / 02期
基金：
美国国家卫生研究院;
关键词：
COVID-19; Coronavirus disease 2019; Drug discovery; SARS-CoV-2; Severe acute respiratory syndrome coronavirus 2; KINASE INHIBITOR; CORONAVIRUS; JAK2; DISCOVERY; EFFICACY; DISEASE; POTENT; INFLAMMATION; MULTICENTER; TOFACITINIB;
D O I：
10.1016/j.drudis.2021.10.016
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
The outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused the unprecedented COVID-19 pandemic, which has infected over 178 million people worldwide. Even with new vaccines, global herd immunity will not be reached soon. New cases and viral variants are being reported at an alarming rate. Effective antiviral treatment is urgently needed. Patients with severe COVID-19 suffer from life-threatening respiratory failure due to acute respiratory distress syndrome in their lungs, a leading cause of COVID-19 mortality. This lung hyper-inflammation is induced by virus-caused massive tissue damage that is associated with uncontrolled cytokine release, known as a cytokine storm, through JAK/STAT signaling pathways. Here, we review the FDA-approved JAK inhibitors that are being clinically evaluated and repurposed for the treatment of patients with severe COVID-19 by calming SARS-CoV-2 infection.
引用
收藏
页码：390 / 400
页数：11
相关论文
共 96 条
  • [31] Immune Response, Inflammation, and the Clinical Spectrum of COVID-19
    Garcia, Luis F.
    [J]. FRONTIERS IN IMMUNOLOGY, 2020, 11
  • [32] Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure
    Giamarellos-Bourboulis, Evangelos J.
    Netea, Mihai G.
    Rovina, Nikoletta
    Akinosoglou, Karolina
    Antoniadou, Anastasia
    Antonakos, Nikolaos
    Damoraki, Georgia
    Gkavogianni, Theologia
    Adami, Maria-Evangelia
    Katsaounou, Paraskevi
    Ntaganou, Maria
    Kyriakopoulou, Magdalini
    Dimopoulos, George
    Koutsodimitropoulos, Ioannis
    Velissaris, Dimitrios
    Koufargyris, Panagiotis
    Karageorgos, Athanassios
    Katrini, Konstantina
    Lekakis, Vasileios
    Lupse, Mihaela
    Kotsaki, Antigone
    Renieris, George
    Theodoulou, Danai
    Panou, Vassiliki
    Koukaki, Evangelia
    Koulouris, Nikolaos
    Gogos, Charalambos
    Koutsoukou, Antonia
    [J]. CELL HOST & MICROBE, 2020, 27 (06) : 992 - +
  • [33] Oclacitinib (APOQUEL®) is a novel Janus kinase inhibitor with activity against cytokines involved in allergy
    Gonzales, A. J.
    Bowman, J. W.
    Fici, G. J.
    Zhang, M.
    Mann, D. W.
    Mitton-Fry, M.
    [J]. JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS, 2014, 37 (04) : 317 - 324
  • [34] Gordon David E, 2020, bioRxiv, DOI 10.1101/2020.03.22.002386
  • [35] IL-6: Relevance for immunopathology of SARS-CoV-2
    Gubernatorova, E. O.
    Gorshkova, E. A.
    Polinova, A. I.
    Drutskaya, M. S.
    [J]. CYTOKINE & GROWTH FACTOR REVIEWS, 2020, 53 : 13 - 24
  • [36] The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status
    Guo, Yan-Rong
    Cao, Qing-Dong
    Hong, Zhong-Si
    Tan, Yuan-Yang
    Chen, Shou-Deng
    Jin, Hong-Jun
    Tan, Kai-Sen
    Wang, De-Yun
    Yan, Yan
    [J]. MILITARY MEDICAL RESEARCH, 2020, 7 (01)
  • [37] Haugh Isabel M, 2018, Proc (Bayl Univ Med Cent), V31, P524, DOI 10.1080/08998280.2018.1480246
  • [38] Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders
    Hexner, Elizabeth O.
    Serdikoff, Cynthia
    Jan, Mahfuza
    Swider, Cezary R.
    Robinson, Candy
    Yang, Shi
    Angeles, Thelma
    Emerson, Stephen G.
    Carroll, Martin
    Ruggeri, Bruce
    Dobrzanski, Pawel
    [J]. BLOOD, 2008, 111 (12) : 5663 - 5671
  • [39] Baricitinib treatment resolves lower-airway macrophage inflammation and neutrophil recruitment in SARS-CoV-2-infected rhesus macaques
    Hoang, Timothy N.
    Pino, Maria
    Boddapati, Arun K.
    Viox, Elise G.
    Starke, Carly E.
    Upadhyay, Amit A.
    Gumber, Sanjeev
    Nekorchuk, Michael
    Busman-Sahay, Kathleen
    Strongin, Zachary
    Harper, Justin L.
    Tharp, Gregory K.
    Pellegrini, Kathryn L.
    Kirejczyk, Shannon
    Zandi, Keivan
    Tao, Sijia
    Horton, Tristan R.
    Beagle, Elizabeth N.
    Mahar, Ernestine A.
    Lee, Michelle Y. H.
    Cohen, Joyce
    Jean, Sherrie M.
    Wood, Jennifer S.
    Connor-Stroud, Fawn
    Stammen, Rachelle L.
    Delmas, Olivia M.
    Wang, Shelly
    Cooney, Kimberly A.
    Sayegh, Michael N.
    Wang, Lanfang
    Filev, Peter D.
    Weiskopf, Daniela
    Silvestri, Guido
    Waggoner, Jesse
    Piantadosi, Anne
    Kasturi, Sudhir P.
    Al-Shakhshir, Hilmi
    Ribeiro, Susan P.
    Sekaly, Rafick P.
    Levit, Rebecca D.
    Estes, Jacob D.
    Vanderford, Thomas H.
    Schinazi, Raymond F.
    Bosinger, Steven E.
    Paiardini, Mirko
    [J]. CELL, 2021, 184 (02) : 460 - +
  • [40] SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor
    Hoffmann, Markus
    Kleine-Weber, Hannah
    Schroeder, Simon
    Krueger, Nadine
    Herrler, Tanja
    Erichsen, Sandra
    Schiergens, Tobias S.
    Herrler, Georg
    Wu, Nai-Huei
    Nitsche, Andreas
    Mueller, Marcel A.
    Drosten, Christian
    Poehlmann, Stefan
    [J]. CELL, 2020, 181 (02) : 271 - +
12345678910